DDX53 and neoplasm: In this context, after 14 days of TPST-1495 treatment therapy, tumor outgrowth was inhibited by 33% inhibition when T cells were depleted and 52% without T-cell depletion, suggesting that the observed anti-CT26 tumor response resulted from both T cell–dependent and T cell–independent mechanisms (Supplementary Fig. S4).